cardiometabolic-disease
(3)
Superluminal Medicines is betting on proteins that refuse to sit still
The Boston biotech designs drugs for receptors in motion. A Lilly partnership and a coming obesity trial will test how much that extra dimension is worth.
Zoe Biosciences Found a Longevity Clue in Amish DNA. Now It Has to Turn That Clue Into a Drug
A rare mutation pointed to longer, healthier lives. Zoe's bet is that two drug programs can borrow the biology without borrowing the mutation - and its newest mouse data put obesity, muscle preservation and a very expensive clinical test on the same page.
Paratus Sciences
Paratus Sciences is a biotechnology company decoding the extreme biology of bats to discover first-in-class medicines. Bats live long, tolerate viruses, resist cancer, control inflammation and thrive on high-sugar diets - traits they evolved over roughly 65 million years. Paratus integrates cell biology, comparative genomics and informatics to translate these adaptations into drug targets for inflammatory and cardiometabolic diseases. Launched in 2023 with a $100M Series A and dual sites in New York and Singapore, its lead program PS-1001 is a first-in-class pan-inflammasome inhibitor.